Delcath Cancer Trials Welcome New Principal Investigator From NCI

NEW YORK, NY, Sep 02 (MARKET WIRE) --
Delcath Systems, Inc. (NASDAQ: DCTH) announced today that the National
Cancer Institute (NCI) has named Dr. Marybeth S. Hughes, MD as the
Principal Investigator for the current Phase III and Phase II clinical
trials of the Company's Percutaneous Hepatic Perfusion (PHP) System.
These trials are being conducted under a Cooperative Research and
Development Agreement (CRADA) between the NCI and Delcath. This
announcement comes as Dr. James F. Pingpank, Jr., who was Principal
Investigator of the trials while at NCI, has assumed the position of
associate professor in the division of surgical oncology at the University
of Pittsburgh School of Medicine. Dr. Pingpank has been named extramural
Adjunct Principal Investigator for the ongoing trials at the NCI.

Dr. Marybeth Hughes, who has been Co-Investigator on these studies since
2004, will provide continued experience and leadership to the trials as
the Phase III study treating metastatic melanoma in the liver continues to
accelerate with the recent announcements that eight additional treatment
centers have joined the trial.

The NCI continues to serve as the lead center for the multi-center Phase
III trial and Steven A. Rosenberg, MD, PhD, Head, NCI Tumor Immunology
Section and Chief, NCI Surgery Branch will continue in his role as
Principal Investigator for all aspects of research under the Cooperative
Research and Development Agreement (CRADA) between NCI and the Company.

On his recent move to UPMC, Dr. Pingpank stated, "UPMC is a recognized
leader in the area of regional cancer therapies. I am delighted to join
the team at The University of Pittsburgh Medical Center, and I look
forward to continue working closely with Dr. Hughes, Dr. Rosenberg and
NCI on these studies."

On these announcements, Richard L. Taney, President and CEO of Delcath,
stated, "We are excited about these recent developments, and the
continuation of our close working relationship with NCI and Dr. Hughes in
her expanded role as Principal Investigator on the study. The NCI's
commitment to the Delcath technology remains instrumental in identifying
clinical and technological improvements to the PHP system and in training
new physicians in the administration of PHP. We are also pleased to
continue our relationship with Dr. Pingpank and look forward to working
with him at UPMC towards completion of the Phase III trial and a variety
of projects to expand the reach of Delcath's technology and establish PHP
as a first-line treatment for liver cancers."

About Delcath Systems, Inc.

Delcath Systems, Inc. is a medical technology company specializing in
cancer treatment. The Company has developed a proprietary, patented system
which will improve the efficacy of cancer treatment while reducing the
considerable, systemic side-effects of chemotherapy. Delcath's novel drug
delivery platform is capable of delivering anti-cancer drugs at very high
doses to a specific organ or region of the body while preventing these
high doses of drug from entering the patient's bloodstream. The Company is
currently enrolling patients in Phase III and Phase II clinical studies
for the treatment of liver cancers using high doses of melphalan. The
Company's intellectual property portfolio consists of twenty-eight patents
on a worldwide basis including the U.S., Europe, Asia and Canada. For more
information, please visit the Company's website at www.delcath.com.

The Private Securities Litigation Reform Act of 1995 provides a safe
harbor for forward-looking statements made by the Company or on its
behalf. This news release contains forward-looking statements, which are
subject to certain risks and uncertainties that can cause actual results
to differ materially from those described. Factors that may cause such
differences include, but are not limited to, uncertainties relating to
our ability to successfully complete Phase III clinical trials and secure
regulatory approval of our current or future drug-delivery system and
uncertainties regarding our ability to obtain financial and other
resources for any research, development and commercialization activities.
These factors, and others, are discussed from time to time in our filings
with the Securities and Exchange Commission. You should not place undue
reliance on these forward-looking statements, which speak only as of the
date they are made. We undertake no obligation to publicly update or
revise these forward-looking statements to reflect events or
circumstances after the date they are made.

Company Contact:
Delcath Systems, Inc.
Richard Taney
(212) 489-2100
Email Contact

Investor Relations Contact:
Strategic Growth International, Inc.
Richard E. Cooper/Cass Almendral
(212) 838-1444
Email Contact
Email Contact

Public Relations Contact:
Rubenstein Associates, Inc.
Robin Wagge
(212) 843-8006
Email Contact

Copyright 2008, Market Wire, All rights reserved.

-0-